Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: unknown, P. 155956 - 155956
Published: April 1, 2025
Language: Английский
International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(24), P. 15585 - 15585
Published: Dec. 9, 2022
The vascular endothelial growth factor (VEGF)/vascular receptor (VEGFR) axis is indispensable in the process of angiogenesis and has been implicated as a key driver tumor vascularization. Consequently, several strategies that target VEGF its cognate receptors, VEGFR-1 VEGFR-2, have designed to treat cancer. While therapies targeting full-length resulted an improvement both overall survival progression-free various cancers, these benefits modest. In addition, inhibition VEGFRs associated with undesirable off-target effects. Moreover, splice variants modulate sprouting non-sprouting identified recent years. Cues within microenvironment determine expression patterns variants. Noteworthy mechanisms action challenge established norm signaling. Furthermore, aberrant some observed cancers. Herein, developments understanding VEGF/VEGFR products molecules, well environmental cues regulate are reviewed. incorporate enhance effectiveness antiangiogenic clinical setting discussed.
Language: Английский
Citations
111
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2024, Volume and Issue: 1879(2), P. 189079 - 189079
Published: Jan. 26, 2024
Language: Английский
Citations
57
Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 14
Published: Jan. 4, 2024
Vascular endothelial growth factors (VEGF), factor receptors (VEGFR) and their downstream signaling pathways are promising targets in anti-angiogenic therapy. They constitute a crucial system to regulate physiological pathological angiogenesis. In the last 20 years, many drugs have been developed based on VEGF/VEGFR treat diverse cancers retinopathies, new with improved properties continue emerge at fast rate. consist of different molecular structures characteristics, which enable them inhibit interaction VEGF/VEGFR, activity VEGFR tyrosine kinase (TK), or signaling. this paper, we reviewed development marketed involved axis, as well some important drug candidates clinical trials. We discuss mode action, benefits, current challenges that will need be addressed by next-generation drugs. focus characteristics each drug, including those approved only China.
Language: Английский
Citations
38
Cells, Journal Year: 2024, Volume and Issue: 13(3), P. 245 - 245
Published: Jan. 28, 2024
Metastatic colorectal cancer remains a deadly malignancy and is the third leading cause of cancer-related death. The mainstay treatment for metastatic chemotherapy, but unfortunately, even with recent progress, overall survival still poor. Colorectal heterogeneous disease, underlying genetic differences among tumors can define behavior prognosis disease. Given limitations cytotoxic research has focused on developing targeted therapy based molecular subtyping. Since early 2000s, multiple therapies have demonstrated efficacy in treating received FDA approval. epidermal growth factor receptor (EGFR), vascular endothelial (VEGF), DNA mismatch repair pathways promising results therapies. As new gene mutations proteins involved oncogenesis are identified, targets will continue to emerge. We herein provide summary updated literature regarding patients mCRC.
Language: Английский
Citations
26
World Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 15(9), P. 1136 - 1156
Published: Aug. 29, 2024
Colorectal cancer (CRC) is the third most common worldwide, and second cause of cancer-related death. In 2020, estimated number deaths due to CRC was approximately 930000, accounting for 10% all worldwide. Accordingly, there a vast amount ongoing research aiming find new improved treatment modalities that can potentially increase survival decrease overall morbidity mortality. Current management strategies include surgical procedures resectable cases, radiotherapy, chemotherapy, immunotherapy, in addition their combination, non-resectable tumors. Despite these options, remains incurable 50% cases. Nonetheless, significant improvements techniques have allowed approaches be frequently updated, leading availability drugs therapeutic strategies. This review summarizes recent CRC, with special emphasis on are currently being studied great potential improve prognosis lifespan patients CRC.
Language: Английский
Citations
20
Frontiers in Cell and Developmental Biology, Journal Year: 2025, Volume and Issue: 12
Published: Jan. 7, 2025
The advent of immune checkpoint inhibitors (ICIs) in colorectal cancer (CRC) treatment marks a major breakthrough. These therapies have proven safer and more effective than traditional radiotherapy targeted treatments. Immunotherapies like pembrolizumab, nivolumab, ipilimumab pioneered new avenues, potentially improving patient outcomes quality life. Additionally, advances immunotherapy prompted detailed research into CRC therapies, especially those integrating ICIs with conventional treatments, providing hope for patients shaping future practice. This review delves the mechanisms various evaluates their therapeutic potential when combined radiotherapy, chemotherapy, clinical settings. It also sheds light on current application involving treatment.
Language: Английский
Citations
2
International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(17), P. 13317 - 13317
Published: Aug. 28, 2023
Vascular endothelial growth factors (VEGFs) are the key regulators of vasculogenesis in normal and oncological development. VEGF-A is most studied angiogenic factor secreted by malignant tumor cells under hypoxic inflammatory stress, which made a rational target for anticancer therapy. However, inhibition monoclonal antibody drugs led to upregulation VEGF-D. VEGF-D was primarily described as lymphangiogenic factor; however, VEGF-D's blood potential comparable has already been demonstrated glioblastoma colorectal carcinoma. These findings suggested role facilitating bypassing anti-VEGF-A antiangiogenic Owing its high mitogenic ability, higher affinity VEGFR-2, expression cancer, might even be stronger driver and, hence, better therapeutic than VEGF-A. In this review, we summarized targetability an therapy cancer.
Language: Английский
Citations
29
Cancer Science, Journal Year: 2024, Volume and Issue: 115(3), P. 734 - 751
Published: Jan. 17, 2024
Abstract The morbidity of colorectal cancer (CRC) has risen to third place among malignant tumors worldwide. In addition, CRC is a common in China whose incidence increases annually. Angiogenesis plays an important role the development because it can bring nutrients that cells need and take away metabolic waste. Various mechanisms are involved formation neovascularization, vascular endothelial growth factor key mediator. Meanwhile, angiogenesis inhibitors drug resistance (DR) challenges consider when formulating treatment strategies for patients with different conditions. Thus, this review will discuss molecules, signaling pathways, microenvironment, treatment, DR CRC.
Language: Английский
Citations
14
Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: 505, P. 158935 - 158935
Published: Jan. 5, 2025
Language: Английский
Citations
1
Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13
Published: Sept. 27, 2022
Colorectal cancer (CRC) is the third most common in world. Although there are standard treatment options for CRC, patients respond poorly to these treatments. Immunotherapies have gradually emerged due increasing awareness and understanding of tumor immunity, exhibiting good therapeutic efficacy various cancers. include cytokines, immune checkpoint inhibitors (ICIs), adoptive cell therapies. In particular, ICIs, which antibodies against cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed death 1 (PD-1), or its ligand PD-L1, been successfully applied clinically solid tumors, relieving inhibitory effect microenvironment on cells. However, only a minority with achieve durable clinical response during immunotherapy. Several factors restrict immunotherapy, leading development drug resistance. this review, we aimed discuss current status immunotherapy CRC elaborate mechanisms that mediate resistance other potential strategies.
Language: Английский
Citations
38